KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Other Gross PP&E Adjustments (2016 - 2025)

Sarepta Therapeutics has reported Other Gross PP&E Adjustments over the past 15 years, most recently at $500.5 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments rose 22.54% year-over-year to $500.5 million; the TTM value through Dec 2025 reached $500.5 million, up 22.54%, while the annual FY2025 figure was $500.5 million, 22.54% up from the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was $500.5 million at Sarepta Therapeutics, up from -$158.0 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $500.5 million in Q4 2025 and troughed at -$170.6 million in Q1 2025.
  • A 5-year average of -$1.8 million and a median of -$81.3 million in 2021 define the central range for Other Gross PP&E Adjustments.
  • Biggest five-year swings in Other Gross PP&E Adjustments: soared 51.32% in 2021 and later tumbled 176.7% in 2023.
  • Year by year, Other Gross PP&E Adjustments stood at $248.9 million in 2021, then increased by 1.21% to $251.9 million in 2022, then rose by 7.58% to $271.0 million in 2023, then skyrocketed by 50.74% to $408.5 million in 2024, then rose by 22.54% to $500.5 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for SRPT at $500.5 million in Q4 2025, -$158.0 million in Q3 2025, and -$169.7 million in Q2 2025.